SmallCaps
ASX:BB1Health Care Equipment & ServicesHealth Care Technology

BlinkLab Ltd

$0.590
$0.035 (5.60%)
Day Range
$0.590 – $0.620
52 Week Range
$0.405 – $1.105
Volume
26.43K
Avg Volume (10D)
150.02K
Market Cap
$90.20M

Price Chart

OHLC · volume · moving averages

$0.590-$0.215 (-26.71%)over 6M
Hi$1.070Lo$0.570
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.620
Previous Close
$0.625
Day High
$0.620
Day Low
$0.590
52 Week High
$1.105
52 Week Low
$0.405

Valuation

Fundamental multiples

Market Cap
90.20M
Shares Outstanding
152.87M
Price to Book
13.79

Trading Activity

Volume & order book

Volume
26.43K
Value Traded
15.80K
Bid
$0.580 × 1,599
Ask
$0.590 × 10,083

Performance

Returns across timeframes

1 Day
-1.53%
5 Day
0.78%
13 Week
-16.77%
52 Week
41.76%
YTD
-20.37%

Technical Indicators

Momentum & moving averages

RSI (14)
37.94
50-Day SMA
$0.663
200-Day SMA
$0.751

— From the desk

Latest News

BlinkLab Dx 1 Device Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial
Technology

BlinkLab Dx 1 Device Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial

BlinkLab (ASX: BB1) has completed a US pilot study evaluating the smartphone-based Dx 1 diagnostic device for the assessment of behavioural and developmental concerns in children, including autism spectrum disorder and attention deficit hyperactivity disorder. The unblinded study involved 485 clinically-diverse children aged between 2 years and 11 years, representing the full spectrum of developmental concerns, […]

BlinkLab partners with INTER-PSY to improve wait times for autism diagnosis in children
Technology

BlinkLab partners with INTER-PSY to improve wait times for autism diagnosis in children

Digital healthcare company BlinkLab (ASX: BB1) has formed a research and clinical partnership with Netherlands-based INTER-PSY to improve wait times for autism diagnosis in children. INTER-PSY offers mental health care, guidance and diagnosis to children and adults with psychological and psychiatric conditions. The partnership will support the adoption of BlinkLab as a diagnostic tool within […]

BlinkLab to advance smartphone-neurobehavioural testing following IPO and ASX debut
Technology

BlinkLab to advance smartphone-neurobehavioural testing following IPO and ASX debut

Neuroscientist-led start-up BlinkLab (ASX: BB1) has made its Australian Securities Exchange (ASX) debut today after an oversubscribed initial public offering raised $7 million to advance a diagnostic tool for neurodevelopmental disorders. The company has committed to the issue of 35 million shares at $0.20 each for an undiluted market capitalisation of $19.8m on listing. The […]